NADAC acquisition cost data for DIFLUNISAL 500 MG TABLET. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00093075501 | $1.05 | 2022-07-20 | Rx |
| 00093075501 | $1.05 | 2022-07-20 | Rx |
| 00093075501 | $1.05 | 2022-07-20 | Rx |
| 00093075501 | $1.05 | 2022-07-20 | Rx |
| 00093075501 | $1.05 | 2022-07-20 | Rx |
| 00093075501 | $1.05 | 2022-07-20 | Rx |
| 00093075501 | $1.05 | 2022-07-20 | Rx |
| 00093075505 | $0.8327 | 2022-12-21 | Rx |
| 00093922201 | $0.8327 | 2022-12-21 | Rx |
| 00093922205 | $0.8327 | 2022-12-21 | Rx |
Generic: Diflunisal | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $2.3M | 23,090 | 8,651 | $1.32 |
| 2020 | $1.8M | 17,066 | 6,081 | $1.28 |
| 2021 | $1.6M | 15,229 | 5,448 | $1.22 |
| 2022 | $903.4K | 9,125 | 3,498 | $1.20 |
| 2023 | $859.2K | 9,240 | 3,325 | $1.07 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| Pennsylvania | $97.4K | 970 | 320 |
| New York | $82.5K | 986 | 414 |
| Michigan | $49.1K | 435 | 180 |
| Massachusetts | $44.5K | 522 | 176 |
| California | $44.5K | 505 | 209 |
| Kentucky | $34.0K | 371 | 127 |
| Texas | $32.5K | 428 | 174 |
| Florida | $31.4K | 329 | 144 |
| Arizona | $28.9K | 238 | 94 |
| Ohio | $27.2K | 262 | 116 |
| Georgia | $24.3K | 274 | 100 |
| Illinois | $23.6K | 303 | 95 |
| Virginia | $22.5K | 249 | 90 |
| Tennessee | $21.5K | 209 | 72 |
| South Carolina | $21.5K | 234 | 94 |
| Missouri | $20.8K | 230 | 52 |
| Minnesota | $17.1K | 184 | 57 |
| Iowa | $16.6K | 162 | 40 |
| Colorado | $16.2K | 159 | 41 |
| Indiana | $16.1K | 157 | 49 |
| Washington | $14.9K | 138 | 41 |
| Wisconsin | $14.1K | 87 | 27 |
| North Carolina | $13.9K | 172 | 82 |
| Vermont | $13.3K | 99 | 29 |
| New Jersey | $12.2K | 163 | 51 |
| Louisiana | $11.2K | 133 | 53 |
| Alabama | $10.7K | 98 | 28 |
| Kansas | $10.7K | 131 | 34 |
| Maryland | $9.6K | 110 | 29 |
| Mississippi | $8.0K | 80 | 26 |
| Connecticut | $7.1K | 137 | 76 |
| West Virginia | $7.0K | 73 | 17 |
| Arkansas | $6.0K | 92 | 45 |
| Nebraska | $5.7K | 67 | 14 |
| New Hampshire | $4.5K | 34 | 13 |
| District of Columbia | $4.5K | 41 | 17 |
| Maine | $4.3K | 58 | 24 |
| Oregon | $4.2K | 49 | 16 |
| Nevada | $3.0K | 21 | N/A |
| Utah | $2.7K | 20 | N/A |
| Delaware | $2.7K | 18 | N/A |
| Puerto Rico | $2.6K | 39 | 18 |
| Oklahoma | $2.6K | 37 | 14 |
| North Dakota | $2.4K | 19 | N/A |
| Montana | $2.4K | 18 | N/A |
| Idaho | $2.2K | 33 | N/A |
| Hawaii | $1.1K | 13 | N/A |
| Wyoming | $335.85 | 22 | 15 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.